Evidence map›Paper›PMID 25010865›Full record

ArticleBritish journal of cancer2014

Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial.

T Veitonmäki, T J Murtola, L Määttänen, K Taari, U-H Stenman, T L J Tammela, A Auvinen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Clinicopathologic Characterization of Prostatic Cancer in Dogs.Animals : an open access journal from MDPI · 2024
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Observational
  10. Review
  11. Article
  12. Article
  13. Aspirin Use Reduces the Risk of Aggressive Prostate Cancer and Disease Recurrence in African-American Men.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2017
    Article
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

T Veitonmäki1] Department of Urology, Tampere University Hospital, Teiskontie 35, 33521 Tampere, Finland [2] School of Health Sciences, University of Tampere, Medisiinarinkatu 3, 33520 Tampere, Finland.
T J Murtola1] Department of Urology, Tampere University Hospital, Teiskontie 35, 33521 Tampere, Finland [2] School of Medicine, University of Tampere, Lääkärinkatu 1, 33520 Tampere, Finland.
L MäättänenFinnish Cancer Registry, Pieni Roobertinkatu 9, 00130 Helsinki, Finland.
K Taari1] Department of Urology, Helsinki University Hospital, Sairaalakatu 1, 01400 Vantaa, Finland [2] School of Medicine, University of Helsinki, Tukholmankatu 8 B, 00014 Helsinki, Finland.
U-H StenmanDepartment of Clinical Chemistry, Helsinki University Hospital, Haartmaninkatu 4, 00290 Helsinki, Finland.
T L J Tammela1] Department of Urology, Tampere University Hospital, Teiskontie 35, 33521 Tampere, Finland [2] School of Medicine, University of Tampere, Lääkärinkatu 1, 33520 Tampere, Finland.
A AuvinenSchool of Health Sciences, University of Tampere, Medisiinarinkatu 3, 33520 Tampere, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe association between nonsteroidal antiinflammatory drugs (NSAIDs) and prostate cancer risk remains controversial. We examined the risk among NSAID users in 78 615 men in the Finnish Prostate Cancer Screening Trial.

methodsWe obtained information on NSAID prescription usage from Finnish nationwide prescription database and on over-the-counter use by a questionnaire. Prostate cancer cases were identified from the Finnish Cancer Registry.

resultsProstate cancer risk was elevated among current NSAID prescription users irrespective of screening (hazard ratio (HR)=1.45, confidence interval (95% CI)=1.33-1.59 and HR=1.71, 95% CI=1.58-1.86 in the screening and control arm, respectively), but not for previous use of NSAIDs. The risk increase was similar among coxib and acetaminophen current users, and stronger for metastatic prostate cancer (HR=2.41, 95% CI=1.59-3.67 and HR=3.44, 95% CI=2.60-4.55 in the screening and control arm, respectively). Previous use of NSAIDs, aspirin use and over-the-counter NSAID usage were not associated with prostate cancer.

conclusionsDiffering association for current and previous use suggests that the risk increase is unlikely to be directly caused by the medication, but may be due to the conditions indicating NSAID prescription usage, such as symptoms of undiagnosed prostate cancer. To reduce inconsistency between the study outcomes, future epidemiological studies on NSAID use and prostate cancer risk should assess the indications for NSAID usage.

Indexed as

AgedAnti-Inflammatory Agents, Non-SteroidalEarly Detection of CancerFinlandHumansIncidenceMaleMiddle AgedProportional Hazards ModelsProstatic NeoplasmsRisk FactorsAnti-Inflammatory Agents, Non-Steroidal

Identifiers

PMID25010865
PMCPMC4183838

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.